ZNTL (Zentalis Pharmaceuticals) Other Financing: $-11.43 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZNTL Zentalis Pharmaceuticals Inc ZNTL
32 GF Score
Price $3.83
! 3 Warning Signs
View Full Analysis

What is Zentalis Pharmaceuticals Other Financing?

Zentalis Pharmaceuticals ZNTL 32 Other Financing is $-11.43 Mil as of Jun. 2026. GuruFocus rates ZNTL with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Zentalis Pharmaceuticals's Other Financing for the three months ended in Jun. 2026 was $0.00 Mil.

Zentalis Pharmaceuticals's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was $-11.43 Mil.

Zentalis Pharmaceuticals Other Financing Historical Data

* Premium members only.

The historical data trend for Zentalis Pharmaceuticals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zentalis Pharmaceuticals Other Financing Chart

Zentalis Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -1.15 0.00 0.00 -0.24 0.00

Zentalis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -9.98 -1.45 0.00
ZNTL
32GF Score
Zentalis Pharmaceuticals Inc ZNTL
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zentalis Pharmaceuticals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-11.43 Mil mean?
Zentalis Pharmaceuticals (ZNTL) has a Other Financing of $-11.43 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Zentalis Pharmaceuticals and its competitors.
Is Zentalis Pharmaceuticals' Other Financing too high?
Zentalis Pharmaceuticals' current Other Financing is $-11.43 Mil. Overall, Zentalis Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Zentalis Pharmaceuticals' Other Financing compare to PROK and LYEL?
Zentalis Pharmaceuticals' Other Financing of $-11.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Zentalis Pharmaceuticals and its competitors. Zentalis Pharmaceuticals's current Other Financing is $-11.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zentalis Pharmaceuticals stock overvalued right now?
Zentalis Pharmaceuticals (ZNTL) has a current Other Financing of $-11.43 Mil. The current Other Financing is $-11.43 Mil. Zentalis Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Zentalis Pharmaceuticals (ZNTL), the current Other Financing is $-11.43 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zentalis Pharmaceuticals Business Description

Address 10275 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
32GF Score

Get the complete analysis for ZNTL

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price